4 completed, 3 active not recruiting, 1 not yet recruiting, 1 recruiting. 7 Phase 1, 2 Phase 2, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 7 | Completed 4, Active not recruiting 2, Recruiting 1 |
| Phase 2 | 2 | Active not recruiting 1, Withdrawn 1 |
| Phase 3 | 1 | Not yet recruiting 1 |
Follow CLR1404: new trials by email Literature Review of CLR1404 trials Research Report on CLR1404
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Evaluation of Iopofosine I 131 vs. R-CD in WM Patients Iopofosine I 131, Rituximab (active comparator), Cyclophosphamate - Waldenstrom Macroglobulinaemia, Waldenstrom Macroglobulinemia | Phase 3 | Not yet recruiting | Cellectar Biosciences, Inc. | 219 | 2026-12-01 | 2026-08-14 |
| Phase 1 Study of CLR 125 in Triple Negative Breast Cancer Iopofosine I 131, CLR 125 - Breast Cancer | Phase 1 | Recruiting | Cellectar Biosciences, Inc. | 60 | 2025-12-05 | 2026-10-08 |
| Novel Targeted Radiotherapy in Pediatric Patients With Inoperable Relapsed or Refractory HGG CLR 131 - High-Grade Glioma | Phase 1 | Active not recruiting | Cellectar Biosciences, Inc. | 50 | 2023-10-01 | 2026-10-01 |
| CLR 131 Combined With Radiation for Head and Neck Cancer CLR 131 - Head and Neck Cancer | Phase 1 | Completed | University of Wisconsin, Madison | 12 | 2019-12-20 | 2025-09-02 |
| Dose Escalation Study of CLR 131 in Pediatric Relapsed/Refractory Malignant Tumors Including Neuroblastoma and Sarcomas CLR 131 - Pediatric Solid Tumor, Pediatric Lymphoma | Phase 1 | Active not recruiting | Cellectar Biosciences, Inc. | 30 | 2019-04-30 | 2026-10-01 |
| Study of Iopofosine I-131 (CLR 131) in Select B-Cell Malignancies (CLOVER-1) With Expansion in Waldenstrom Iopofosine I 131 single dose, Iopofosine I 131 multiple dose, Iopofosine I 131 fractionated dose - Waldenstrom Macroglobulinemia, Multiple Myeloma | Phase 2 | Active not recruiting | Cellectar Biosciences, Inc. | 120 | 2017-07-26 | 2026-03-18 |
| Dose Escalation Study of I-131-CLR1404 in Patients With Relapsed or Refractory Multiple Myeloma I-131-CLR1404, dexamethasone - Multiple Myeloma | Phase 1 | Completed | Cellectar Biosciences, Inc. | 31 | 2015-02-01 | 2023-02-22 |
| Open-Label Study of I-131-CLR1404 in Subjects With Recurrent Glioma I-131-CLR1404 Injection - Glioma | Phase 2 | Withdrawn | Cellectar Biosciences, Inc. | 2014-05-01 | 2014-02-25 | |
| Dose Escalation Study of I-131-CLR1404 in Subjects With Cancer That Does Not Respond to Treatment or Has Returned I-131-CLR1404 - Cancer | Phase 1 | Completed | Cellectar Biosciences, Inc. | 12 | 2011-12-01 | 2015-02-26 |
| Dosimetry Study of I-131-CLR1404 in Patients With Relapsed or Refractory Advanced Solid Tumors I-131-CLR1404 - Solid Tumors | Phase 1 | Completed | Cellectar, Inc | 9 | 2009-06-01 | 2010-05-04 |
Glioma (3) · Neoplasms (3) · Recurrence (3) · Lymphoma (2) · Lymphoma, Non-Hodgkin (2) · Multiple Myeloma (2) · Sarcoma (2) · Triple Negative Breast Neoplasms (2) · Waldenstrom Macroglobulinemia (2) · Blood Protein Disorders (1) · Breast Neoplasms (1) · Carcinoma, Non-Small-Cell Lung (1) · Colorectal Neoplasms (1) · Desmoplastic Small Round Cell Tumor (1) · Diffuse Intrinsic Pontine Glioma (1)
Cellectar Biosciences, Inc. (8) · Cellectar, Inc (1) · University of Wisconsin, Madison (1)
United States (9) · Australia (2) · Canada (2) · Brazil (1) · Czechia (1) · Finland (1) · France (1) · Greece (1) · Israel (1) · Spain (1) · Turkey (Türkiye) (1) · United Kingdom (1)
Jarrod Longcor (4) · Glen Liu, M.D (1) · Justine Bruce, MD (1) · Minesh Mehta, M.D., FASTRO (1) · Natalie S Callander, MD (1)
P50DE026787 (1)